More recently, a benefit in survival has been also reported in patients with advanced CRC with two new promising antiangiogenic drugs: aflibercept (a VEGF trap) in combination with FOLFIRI (folinic acid, 5-fluoruracil and irinotecan) following progression to oxaliplatin-based therapy[6], and regorafenib (a novel tyrosine kinase inhibitor targeting VEGFR, PDGFR, FGFR, RET, KIT and TIE2) as single-agent therapy in patients who had progressed to all standard therapies[7]. The gene discussed is KIT; the disease is colorectal carcinoma.